Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Juvenile Idiopathic Arthritis (JIA) in 8 Major Markets
Juvenile Idiopathic Arthritis (JIA) is an auto-immune disorder defined as inflammation of the joints. For diagnosis, the inflammation in one or more of the joints must be present for at least six weeks, affecting children under the age of 16. There are 6 main types of JIA: systemic, oligoarticular, polyarticular, psoriatic, enthesitis-related and undifferentiated. Patients with JIA have a prolonged inflammatory response, and the reasons for these excessive inflammatory responses are still unknown.
This report provides the current prevalent population for JIA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of JIA have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for JIA include:
• Uveitis and associated complications
• Iridiocyclitis
• Joint and muscle pain
• Osteoporosis
• Osteopenia
• Macrophage Activation Syndrome
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global JIA’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of JIA and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on JIA’s prevalent population.
• Identify sub-populations within JIA which require treatment.
• Gain an understanding of the specific markets that have the largest number of JIA patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions /Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Prevalence for Juvenile Idiopathic Arthritis
• Features of Juvenile Idiopathic Arthritis Patients
o Type and Classification of JIA
o Number of Joints Affected in JIA Patients
o Anti-nuclear antibodies & Erythrocytes in JIA
o Uveitis and Associated Conditions in JIA
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Figures
• JIA prevalence across the 8 Major Markets in 2016
List of Tables
• Steinbrocker criteria for classification of functional impairment
• Prevalence of JIA, total (000s)
• Prevalence of JIA, males (000s)
• Prevalence of JIA, females (000s)
• Type of JIA in patients, total (000s)
• Rheumatoid factor status in polyarticular JIA patients, total (000s)
• Childhood Health Assessment Questionnaire scores of JIA patient disability, total (000s)
• Steinbrocker functional class of JIA patients, total (000s) 13
• Number of swollen joints of JIA patients, total (000s)
• Number of active joints of JIA patients, total (000s)
• Number of restricting joints of JIA patients, total (000s)
• JIA patients with anti-nuclear antibodies, total (000s)
• JIA patient types with anti-nuclear antibodies, total (000s)
• ESR of JIA patients, total (000s)
• Prevalence of uveitis in JIA patients, total (000s)
• Prevalence of uveitis in JIA patient types, total (000s)
• Prevalence of cataracts in uveitis JIA patients, total (000s)
• Prevalence of glaucoma in uveitis JIA patients, total (000s)
• Prevalence of band keratopathy in uveitis JIA patients, total (000s)
• Prevalence of synechiae in uveitis JIA patients, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of JIA by 5-yr age cohort, males (000s)
• USA Prevalence of JIA by 5-yr age cohort, females (000s)
• France Prevalence of JIA by 5-yr age cohort, males (000s)
• France Prevalence of JIA by 5-yr age cohort, females (000s)
• Germany Prevalence of JIA by 5-yr age cohort, males (000s)
• Germany Prevalence of JIA by 5-yr age cohort, females (000s)
• Italy Prevalence of JIA by 5-yr age cohort, males (000s)
• Italy Prevalence of JIA by 5-yr age cohort, females (000s)
• Spain Prevalence of JIA by 5-yr age cohort, males (000s)
• Spain Prevalence of JIA by 5-yr age cohort, females (000s)
• United Kingdom Prevalence of JIA by 5-yr age cohort, males (000s)
• United Kingdom Prevalence of JIA by 5-yr age cohort, females (000s)
• Brazil Prevalence of JIA by 5-yr age cohort, males (000s)
• Brazil Prevalence of JIA by 5-yr age cohort, females (000s)
• Japan Prevalence of JIA by 5-yr age cohort, males (000s)
• Japan Prevalence of JIA by 5-yr age cohort, females (000s)
